JP2021531249A5 - - Google Patents

Info

Publication number
JP2021531249A5
JP2021531249A5 JP2020573469A JP2020573469A JP2021531249A5 JP 2021531249 A5 JP2021531249 A5 JP 2021531249A5 JP 2020573469 A JP2020573469 A JP 2020573469A JP 2020573469 A JP2020573469 A JP 2020573469A JP 2021531249 A5 JP2021531249 A5 JP 2021531249A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
formula
pharmaceutical composition
compound according
solvates
Prior art date
Application number
JP2020573469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531249A (ja
JPWO2020014409A5 (https=
JP7444797B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041283 external-priority patent/WO2020014409A1/en
Publication of JP2021531249A publication Critical patent/JP2021531249A/ja
Publication of JPWO2020014409A5 publication Critical patent/JPWO2020014409A5/ja
Publication of JP2021531249A5 publication Critical patent/JP2021531249A5/ja
Priority to JP2024025112A priority Critical patent/JP2024059789A/ja
Application granted granted Critical
Publication of JP7444797B2 publication Critical patent/JP7444797B2/ja
Priority to JP2025120296A priority patent/JP2025157418A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020573469A 2018-07-11 2019-07-11 老化細胞除去組成物及びその使用 Active JP7444797B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024025112A JP2024059789A (ja) 2018-07-11 2024-02-22 老化細胞除去組成物及びその使用
JP2025120296A JP2025157418A (ja) 2018-07-11 2025-07-17 老化細胞除去組成物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696486P 2018-07-11 2018-07-11
US62/696,486 2018-07-11
PCT/US2019/041283 WO2020014409A1 (en) 2018-07-11 2019-07-11 Senolytic compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024025112A Division JP2024059789A (ja) 2018-07-11 2024-02-22 老化細胞除去組成物及びその使用

Publications (4)

Publication Number Publication Date
JP2021531249A JP2021531249A (ja) 2021-11-18
JPWO2020014409A5 JPWO2020014409A5 (https=) 2022-07-19
JP2021531249A5 true JP2021531249A5 (https=) 2022-07-19
JP7444797B2 JP7444797B2 (ja) 2024-03-06

Family

ID=69140375

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020573469A Active JP7444797B2 (ja) 2018-07-11 2019-07-11 老化細胞除去組成物及びその使用
JP2024025112A Pending JP2024059789A (ja) 2018-07-11 2024-02-22 老化細胞除去組成物及びその使用
JP2025120296A Pending JP2025157418A (ja) 2018-07-11 2025-07-17 老化細胞除去組成物及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024025112A Pending JP2024059789A (ja) 2018-07-11 2024-02-22 老化細胞除去組成物及びその使用
JP2025120296A Pending JP2025157418A (ja) 2018-07-11 2025-07-17 老化細胞除去組成物及びその使用

Country Status (9)

Country Link
US (3) US11026963B2 (https=)
EP (1) EP3790861A4 (https=)
JP (3) JP7444797B2 (https=)
KR (1) KR102843318B1 (https=)
CN (2) CN120136941A (https=)
IL (2) IL312612A (https=)
MX (2) MX2021000395A (https=)
SG (1) SG11202012099VA (https=)
WO (1) WO2020014409A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN115397811B (zh) 2020-01-20 2025-05-23 奈奥芬莱有限公司 与atp结合位点结合的异吲哚啉衍生物
JP2023527869A (ja) * 2020-06-01 2023-06-30 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢関連障害の治療法
GB202008201D0 (en) 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
WO2023039293A1 (en) * 2021-09-13 2023-03-16 Rubedo Life Sciences, Inc. Coumarin derivatives of sugar analogs and uses thereof
CN118475356A (zh) * 2021-09-13 2024-08-09 鲁贝多生命科学公司 糖衍生物的药物偶联物及其作为衰老细胞裂解剂的用途
US11897915B2 (en) * 2021-09-13 2024-02-13 Rubedo Life Sciences, Inc. Sugar derivatives and uses thereof to prepare novel senolytic agents
CN114249782B (zh) * 2022-01-05 2023-06-30 湖南大学 一种选择性破坏衰老细胞溶酶体的前药及其制备方法与应用
CN118434454A (zh) * 2022-08-19 2024-08-02 北京三秀生物医药科技有限公司 一种抗衰老相关疾病的前药及其使用方法
CN118496288B (zh) * 2023-02-06 2025-01-10 中国科学院微生物研究所 一种糖基化喜树碱类化合物Gly-CPTR及其制药用途、药物或前药及制备方法
EP4687893A1 (en) * 2023-04-06 2026-02-11 Integrated Biosciences, Inc. Compounds and uses thereof
CN116688159A (zh) * 2023-06-19 2023-09-05 江西德上制药股份有限公司 一种基于mRNA技术治疗阿尔茨海默病的药物组合物及制备方法
CN116942653A (zh) * 2023-08-25 2023-10-27 徐诺药业(南京)有限公司 艾贝司他用于制备防治细胞因子风暴相关疾病药物的用途
WO2025175039A1 (en) * 2024-02-13 2025-08-21 Luxvitae Therapeutics Inc. Duocarmycin analogs and applications thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US6664443B1 (en) 1998-05-01 2003-12-16 Mayo Foundation For Medical Education And Research Pathogenic Tau mutations in transgenic mice
EA200601252A1 (ru) 1999-09-08 2006-10-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
CN1257190C (zh) 2003-04-02 2006-05-24 郭全太 聚葡萄糖生产工艺
EP1973872A4 (en) 2006-12-19 2012-05-09 Methylgene Inc HISTONDEACETYLASE HEMMER AND PROPHARMAKA THEREOF
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
MX2010003113A (es) * 2007-09-25 2010-04-01 Abbott Lab Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina.
US20110053991A1 (en) * 2007-11-19 2011-03-03 Gore Lia Treatment of Histone Deacetylase Mediated Disorders
US8278436B2 (en) * 2008-07-30 2012-10-02 Wisconsin Alumni Research Foundation Glycosylated warfarin analogs and uses thereof
JP5765239B2 (ja) * 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
US20120005765A1 (en) 2010-07-01 2012-01-05 Saint Louis University Animal model for parkinson's disease
JP6250394B2 (ja) 2010-08-19 2017-12-20 バック・インスティテュート・フォー・リサーチ・オン・エイジング 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
CN103261200B (zh) * 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
KR20140119023A (ko) 2011-12-13 2014-10-08 버크 인스티튜트 포 리서치 온 에이징 의료 요법을 개선하는 방법
JP6328098B2 (ja) 2012-03-29 2018-05-23 フィリップス ライティング ホールディング ビー ヴィ 暖房デバイス及び暖房方法
DK2890981T3 (en) * 2012-08-28 2019-03-04 Univ Tuebingen Medizinische Fakultaet Senescence tracers
WO2014205244A1 (en) 2013-06-19 2014-12-24 Demaria Marco Methods for enhancing effectiveness of medical therapies
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
EP3139942B1 (en) 2014-05-05 2019-12-18 Bioventures, Llc COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
ES2895174T3 (es) * 2014-09-29 2022-02-17 Scripps Research Inst Moduladores del receptor de esfingosina-1-fosfato para el tratamiento de trastornos cardiopulmonares
WO2016118859A1 (en) 2015-01-22 2016-07-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells comprising flip
CA2981753A1 (en) * 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditions
JP6936498B2 (ja) 2016-04-21 2021-09-15 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用
WO2018146506A1 (en) 2017-02-10 2018-08-16 Universitat Politècnica De València Therapeutic derivatives

Similar Documents

Publication Publication Date Title
JP2021531249A5 (https=)
JPWO2020014409A5 (https=)
RU2494095C2 (ru) Модифицированные миметики лизина
JP2007519619A5 (https=)
JPS6197256A (ja) アルキルスルホンアミドフエニルアルキルアミン類
WO2008054454A2 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
ES2428539T3 (es) Nuevos inhibidores de histona deacetilasas
JP2016539140A (ja) ヒストンデアセチラーゼ阻害剤と免疫調節薬の組合せ
IE920404A1 (en) Compounds
JP2016501241A5 (https=)
RU97103207A (ru) Арилтиосоединения в качестве антибактериальных и противовирусных средств
JPH11503746A (ja) サクシンアミド誘導体と金属タンパク質分解酵素阻害剤としてのその使用
CZ283602B6 (cs) Pyrrolidinové deriváty, způsob jejich přípravy a léčiva tyto deriváty obsahující
CN102781443A (zh) 用于治疗结节病的阿普斯特
JP2007530694A5 (https=)
EP0793641B1 (en) Metalloproteinase inhibitors
JPH05506643A (ja) Ｎ―フエニル―ｎ―アセトアミドグリシンアミド類、それらの製造およびそれらを含有する薬物
US20080188565A1 (en) Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
KR20200075867A (ko) 단백 분해 효소의 쌍두형 저해제
JP2009040767A5 (https=)
JPS6327426A (ja) 胃腸疾患処置剤フェニルエタノ−ルアミン誘導体類
FR2901273A1 (fr) Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
JP3647451B2 (ja) ベンゾラクタム誘導体
RU2013113301A (ru) Замещенные 2-оксо- и 2-тиоксо-дигидрохинолин-3-карбоксамиды в качестве модуляторов kcnq2/3
AP694A (en) Nitro-benzamides useful as anti-arrhythmic agents.